Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Caribou Biosciences (CRBU) Research & Development (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Research & Development for 6 consecutive years, with $23.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development fell 21.83% to $23.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $112.4 million, a 13.65% decrease, with the full-year FY2025 number at $109.4 million, down 15.92% from a year prior.
  • Research & Development was $23.8 million for Q4 2025 at Caribou Biosciences, down from $27.7 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $35.5 million in Q2 2024 to a low of $10.2 million in Q1 2021.
  • A 5-year average of $23.9 million and a median of $25.7 million in 2022 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: soared 156.2% in 2021, then decreased 21.95% in 2025.
  • Caribou Biosciences' Research & Development stood at $15.1 million in 2021, then surged by 70.31% to $25.7 million in 2022, then rose by 21.54% to $31.3 million in 2023, then dropped by 2.61% to $30.5 million in 2024, then dropped by 21.83% to $23.8 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Research & Development are $23.8 million (Q4 2025), $27.7 million (Q2 2025), and $30.5 million (Q4 2024).